Interventions to Increase Completion of Hepatitis B Vaccination in People who Inject Drugs: A Systematic Review and Meta-analysis

Stacy Tressler
Ruchi Bhandari

Follow this and additional works at: https://researchrepository.wvu.edu/faculty_publications

Part of the Epidemiology Commons
Interventions to Increase Completion of Hepatitis B Vaccination in People who Inject Drugs: A Systematic Review and Meta-analysis

Stacy Tressler and Ruchi Bhandari
Department of Epidemiology, West Virginia University, Morgantown, West Virginia, USA

Increases in opioid misuse and injection drug use have resulted in a rise in acute cases of hepatitis B. We conducted a systematic review and meta-analysis of randomized studies to determine the effect (pooled odds ratio) of interventions to increase hepatitis B vaccination completion in people who inject drugs (PWID). Odds ratios from the included studies were combined to create a pooled odds ratio (OR) using the Inverse Heterogeneity Model. Eleven studies met the eligibility criterion of having a randomized intervention to increase hepatitis B virus vaccination completion among PWID. The odds of vaccine completion in the intervention group were greater than in the control/comparison group (pooled OR, 2.53; 95% confidence interval [CI], 1.07–5.99). Subgroup analysis indicated that financial incentives were most effective (OR, 7.01; 95% CI, 2.88–17.06), followed by accelerated vaccine schedules (OR, 1.90; 95% CI, 1.14–3.14). Interventions using financial incentives and accelerated vaccine schedules are moderately effective at increasing hepatitis B vaccination completion in PWID.

Keywords: hepatitis B; meta-analysis; people who inject drugs; vaccination.

Globally, ~90% of the world’s population lives in countries with a high or intermediate prevalence of hepatitis B [1]. Worldwide, ~240 million people are chronically infected with hepatitis B virus (HBV), and in the United States, an estimated 2.2 million people are chronic carriers of the virus [2, 3]. It is estimated that chronic hepatitis B (CHB) infection is responsible for 50% of all cases of hepatocellular carcinoma, and 25% of people with CHB will die prematurely from complications of the disease [1].

Major risk factors for HBV infection in the United States include sexual exposure and injection drug use (IDU) [4]. Since 2009, opioid misuse and IDU in the United States have resulted in an increase in acute cases of hepatitis B [2]. In 2015, 30.3% of newly HBV-infected people reported IDU as a risk factor [4]. Adults with compromised immune systems are more likely to develop chronic infection (20%) compared with those with a healthy immune system (5%) [1]. People who inject drugs (PWID) have a higher risk of developing chronic infection due to altered immune function and co-infections with hepatitis C virus (HCV) and HIV [5].

The rise in opioid misuse and IDU has highlighted the need to provide education and harm reduction services to PWID, including HBV vaccination [2, 6]. Survey data from 2013 indicate that only one-third of adults have completed the 3-dose HBV vaccination series, and this number is estimated to be even lower in PWID [2]. PWID can be a difficult population to reach, and completion of the standard 3-dose series at 0, 1, and 6 months in this population can be challenging. For this reason, different strategies have been used to increase vaccination rates, including accelerated vaccine schedules, financial incentives, case management, peer coaching, and motivational interviewing [7–17]. In 2014, The World Health Organization (WHO) published guidance on preventing HBV and HCV in PWID. Using a systematic review approach, the authors graded the quality of evidence for using an accelerated vaccine schedule, financial incentives, and peer-based strategies to improve health outcomes for people with substance use disorders [3]. Although the quality of the evidence supporting these strategies was low, the WHO recommends their use to prevent the transmission of HBV and HCV in PWID [3].

Objective
The primary objective of this study was to conduct a systematic review and meta-analysis of randomized controlled trials and randomized studies to determine the overall effect of strategies to increase HBV vaccination in PWID.

METHODS

Study Eligibility
The eligibility criteria for inclusion in this systematic review with meta-analysis were established a priori. Each study was
required to meet the following eligibility criteria: (1) randomized controlled trial or randomized study with at least 1 intervention group and 1 control/comparison group, (2) intervention aimed at increasing adherence to completion of the HBV vaccine series as either a primary or secondary outcome, (3) outcome data available on completion of the 3-dose HBV vaccination series, and (4) a study sample that included PWID (representing either all or a percentage of the overall study sample). The gray literature was not searched, and only studies published in English were included.

Data Sources
An electronic search of PubMed, Web of Science, and Cochrane Library was performed on February 20, 2018. Search terms included “inject*”, “drug use*”, “hepatitis B vacc*”, and “hepatitis B vaccine*.” MESH terms included “hepatitis B vaccines” and “substance abuse, intravenous.” There were no time restrictions placed on the search, and each database was searched from its inception through February 20, 2018. Hand-searching of references was performed when reviewing relevant studies to identify randomized controlled trials (RCTs) not found during the electronic search. An additional search of the 3 databases was performed on June 19, 2019, to search for studies meeting the inclusion criteria that were published between February 20, 2018, and June 19, 2019. No additional studies were identified.

Study Selection
Studies obtained from the search results were imported into EndNote (VXE; Thomas Reuters, New York, NY, USA). Duplicates were identified and removed. Titles and abstracts were reviewed to identify studies meeting the inclusion criteria. A flowchart detailing the exclusion process and the reasons for exclusion can be found in Figure 1. For studies using the same sample, the study with the data most relevant to the review topic was selected.

Data Extraction
Microsoft Excel (version 2010; Richmond, WA, USA) was used to develop a codebook for data extraction before article selection. Each study was coded on 51 items, including the following major categories of variables: (1) study characteristics, (2) intervention characteristics, (3) participant characteristics, and (4) outcome characteristics. For studies with >1 intervention group, outcome data for the most intensive intervention were selected. If a true control group did not exist, the comparison group selected by the study authors was used. Data were included in the meta-analysis even if studies reported outcome data for a PWID subpopulation.

Risk of Bias Assessment
Risk of bias was assessed for each included study using the Cochrane Risk of Bias tool [18]. Study bias was assessed as high,
low, or unclear on the following measures: (1) random sequence
generation, (2) allocation concealment, (3) blinding of partici-
pants and personnel, (4) blinding of outcome data, (5) incom-
plete outcome data, (6) selective reporting, and (7) other major
sources of bias.

Statistical Analysis
All analyses were completed in Meta XL using the Inverse
Heterogeneity Model (IVhet). Data on studies reporting ad-
justed and crude odds ratios (ORs) of completion of the 3-dose
HBV vaccination series in the intervention group compared
with the control/comparison group were entered into Meta XL.
Adjusted and crude odds ratios were pooled to create an overall
effect size. Pooled ORs with 95% confidence intervals (CIs)
were calculated using the IVhet in Meta XL. Heterogeneity and
inconsistency were assessed using the Q statistic (based on the
chi-square test statistic) and $I^2$. For the Q statistic, a $P$ value <.10
was indicative of statistically significant heterogeneity between
studies. $I^2$ scores of 25% (low), 50% (moderate), and 75% (high)
were used to determine the amount of inconsistency between
studies. Small-study effects were assessed using a funnel plot.
Cumulative, influence, and subgroup analyses were conducted.
Subgroup analyses included intervention type (accelerated, fi-
nancial, and case management or enhanced services) and re-
ported OR (adjusted vs crude).

RESULTS

Study Characteristics
A flowchart depicting the search strategy and study selection
process can be found in Figure 1. A total of 565 studies were
identified through electronic database searches. An additional
3 studies were identified through hand-searching references
during review of full articles, for a total of 568 studies. Using
both electronic and manual searching methods, 72 duplic-
ates were identified and removed. A total of 496 studies were
screened for eligibility, resulting in the removal of 485 studies.

Eleven studies, representing 4027 participants, met the selection
criteria and were included in the meta-analysis. All of the
studies included adherence to the 3-dose HBV vaccine series as
their primary outcome. Countries where the studies were con-
ducted included the United States (n = 7) Iran (n = 1), Denmark
(n = 1), Australia (n = 1), and the United Kingdom (n = 1).
Study settings included prison (n = 2), syringe exchange pro-
gram (n = 2), methadone maintenance program (n = 2), drug
treatment program (n = 2), community (n = 1), streets in an
urban area (n = 1), and a combination of shelters, drug treat-
ment facility, and streets (n = 1). An overview of study charac-
teristics can be found in Table 1.

Participant Characteristics
The mean age of participants ranged from 34 to 46.3 years.
Studies had a greater proportion of males compared with
females, with a range of 55% to 100% males. The studies varied
on the percentage of participants who reported IDU and ranged
from 8.9% to 100%. Five studies included only participants who
reported IDU, and the other 6 studies included participants
who reported IDU and other alcohol/drug use. Ten studies
based IDU on self-report, and each study differed on whether
the IDU was classified as current, recent, ever/lifetime, or fu-
ture risk. The only common variables reported for all 11 studies
were percent IDU and percent males. Participant characteristics
can be found in Table 1.

Intervention Characteristics
Interventions were classified into 3 main categories: (1) HBV
care coordination. Study characteristics can be found in Table 1.

Risk of Bias Assessment
The Cochrane Risk of Bias assessment tool was used to rank
the studies as having high, low, or unclear risk of bias on 7 do-
mains (Supplementary Figure 1). Due to the nature of the inter-
ventions, almost all studies were ranked as having a high risk
of bias, based on 3 criteria: allocation concealment, blinding
of participants and personnel, and blinding of outcome re-
porting. For all studies, the risk of bias for selective outcome re-
porting was low. The risk of bias varied among studies for the
other 3 criteria, namely random sequence generation, incom-
plete outcome data, and other issues.

Data Synthesis
Results of the OR for vaccine completion in the interven-
tion group compared with the control/comparison group can
be found in Figure 2. An overall pooled OR of 2.53 (95% CI,
1.07–5.99) indicated a statistically significant ($P = .04$) increase
in the odds of completing the 3-dose vaccine in the interven-
tion groups compared with the control/comparison group.
Study heterogeneity was statistically significant ($P < .0001$),
and inconsistency was categorized as high ($I^2 = 89$%). An in-
fuence analysis with each study excluded once revealed that
results did not remain statistically significant when 4 of the 11
studies were individually removed from the model once. The
results of the influence analysis can be found in Supplementary
Table 1. A cumulative meta-analysis of the studies by year
(Supplementary Figure 2) showed that the ORs in the studies
| Study | Country | Setting | Type of Intervention | Intervention | Control | Randomized & Vaccine Eligible, No. | Type of Intervention | Mean Age, y | Male, % | IDU, % | Notes |
|-------|---------|---------|---------------------|--------------|---------|-----------------------------------|---------------------|--------------|--------|--------|-------|
| Asli et al. | Iran | Prison and corrections facility | RCT | 169 | Vaccine schedule 0, 1, 4, 8 wk | Standard vaccine schedule | 34 | 100 | 8.9 (history of) |
| Bowman et al. | United States | Syringe exchange program | Randomized | 461 | Vaccine schedule 0, 1, 2 mo | Standard vaccine schedule | 40.4a | 73a | 100 (past 30 d) |
| Christensen et al. | Denmark | Prison | Randomized | 34 | Vaccine schedule 0, 1, 3 wk | Standard vaccine schedule | b | b | 100 (IDU ever) |
| Hwang et al. | United States | Community RCT | 1260 | Vaccine schedule 0, 1, 2 mo | Standard vaccine schedule | c | 77 | 30 (IDU ever) |
| Masson et al. | United States | Methadone maintenance programs | RCT | 300 | Case management/ enhanced services | Enhanced care coordination | 44.85 | d | 68 | 70 (IDU ever) |
| Nyamathi et al. | United States | Homeless shelters, residential drug treatment programs, and outdoor areas | Randomized | 865 | Nurse case management, $5 incentive per dose and tracking | Standard hepatitis training with $5 incentive per dose | 42.3 | 76.7 | 16.7 (lifetime) |
| Nyamathi et al. | United States | Residential drug treatment programs (urban) | Randomized | 345 | Case management/ enhanced services | Intensive peer coaching and nurse case management | 42 | 100 | 32.5 (lifeline) |
| Nyamathi et al. | United States | Methadone maintenance treatment programs (urban) | RCT | 148 | Case management/ enhanced services | Nurse-led hepatitis health promotion | 46.3 | 55 | 34.4 (recent) |
| Seal et al. | United States | Community-recruited RCT | RCT | 96 | Monetary | $20 monthly for 6 months | 43 | 72 | 100 (current) |
| Topp et al. | Australia | Inner-city health service | RCT | 139 | Monetary | $20 at first visit, AU $30 at second visit, AU $30 at third visit, and AU $30 at follow-up visit | 33.1 | 33.1 | 77 | 100 (previous, current, or at-risk for future) |
| Weaver et al. | United Kingdom | Drug treatment centers Cluster RCT | Monetary | 210 | Monetary | Treatment as usual with no incentive | 36.2 | 80 | 100 (prevous, current, or at-risk for future) |

*For the original paper, see Heimer et al. paper [22].
**Did not report demographic information for the randomized controlled trial.
***Not reported.

Abbreviations: IDU, injection drug use; MI, motivational interviewing; RCT, randomized controlled trial.
have decreased since 2003 and have not remained statistically significant. Small-study bias was assessed using a funnel plot (Supplementary Figure 3), plotting the natural log OR for each study against its precision. Asymmetry in the funnel plot indicated potential small-study effects or other sources of bias such as true heterogeneity between studies. Two subgroup analyses were conducted to explore this heterogeneity. Figure 2 illustrates the forest plot of the overall meta-analysis results using the Inverse Heterogeneity Model. Figure 3 shows the forest plot of subgroup analysis by intervention type using the Inverse Heterogeneity Model.
comparing results by type of intervention and type of OR were included in the analysis. Intervention types were categorized as vaccine schedule, monetary/financial incentives, and case management/enhanced services (Figure 3). For the vaccine schedule subgroup, the pooled OR was 1.90 (95% CI, 1.14–3.14), heterogeneity was not statistically significant (P = .13), and inconsistency was moderate (I² = 47%). The pooled OR for the monetary subgroup was 7.01 (95% CI, 2.88–17.06), heterogeneity was not statistically significant (P = .12), and inconsistency was moderate (I² = 53%). The case management/enhanced services subgroup pooled OR was not statistically significant (OR, 2.92; 95% CI, 0.54–15.66), heterogeneity was statistically significant (P < .0001), and inconsistency was high (I² = 96%). Finally, the subgroup analysis of crude vs adjusted OR yielded the following results: the pooled OR for studies that reported adjusted ORs was 2.26 (95% CI, 1.02–4.97), heterogeneity was statistically significant (P < .0001), and inconsistency was high (I² = 77%); the pooled OR for studies that reported crude ORs was 3.04 (95% CI, 0.49–18.88), heterogeneity was statistically significant (P < .0001), and inconsistency was high (I² = 94%) (Figure 4).

DISCUSSION

This systematic review and meta-analysis included 11 RCTs or randomized studies that implemented strategies to increase completion of the 3-dose HBV vaccine series in PWID. The pooled OR for all 11 studies indicated a statistically significant increase in the odds of completing all 3 doses in the intervention group compared with the control/comparison group (OR, 2.53; 95% CI, 1.07–5.99; P = .04). Subgroup analyses comparing the interventions by type indicated that the odds of vaccine completion in those who received financial incentives was the highest, followed by receipt of an accelerated vaccine schedule. Subgroup analysis of the case management/enhanced services group yielded an OR that was not statistically significant. These findings are consistent with WHO recommendations from 2014 that were based on previous research to increase compliance with HBV vaccination in PWID [3].

Hepatitis B is a vaccine-preventable disease that remains problematic in certain at-risk groups. Since 2009, the increase in IDU in the United States has highlighted the importance of providing harm-reduction services to PWID, including access to HBV vaccine. However, making the vaccine available does not always translate to increased HBV vaccination rates in PWID. Strategies are needed to increase the vaccine uptake among this at-risk group. The cost of the vaccine is minimal compared with the savings from improved quality of life and reduced health care costs. In 1 study, the cost of providing financial incentives to increase vaccine compliance was $220 per participant compared with the cost of increasing compliance through outreach methods, which equaled $590 per participant [7]. Combining financial incentives with an accelerated vaccine schedule represents a low-cost and effective method for increasing compliance.

Figure 4. Forest plot of subgroup analysis by type of reported odds ratio using the Inverse Heterogeneity Model. Abbreviations: aOR, adjusted odds ratio; IVhet OR, Inverse Heterogeneity Model odds ratio; OR, odds ratio.
In 2017, the Food and Drug Administration approved Heplisav-B, a new 2-dose, highly immunogenic hepatitis B vaccine [19]. The new 2-dose series is administered at 0 and 30 days, compared with the traditional series administered at 0, 1, and 6 months. Use of the 2-dose series in future vaccine interventions among PWID may increase adherence and result in a higher immune response compared with the traditional 3-dose series. However, results from a recent study indicated that the percentage of at-risk people completing the second dose of the traditional HBV vaccine series was only 40.4%, suggesting a need to incorporate strategies to increase HBV vaccine schedule adherence even for a 2-dose series [20].

More randomized controlled studies are needed to examine the effectiveness of interventions specifically in PWID. Based on findings from the Hu et al. (2008) study, administering the first dose of HBV in conjunction with testing for HBV is both cost-saving and effective and should be considered when conducting future research [21]. Additionally, combining different strategies, for example, accelerated vaccine schedules with financial incentives, may confound the association and make it difficult to determine the effectiveness of the individual intervention. Therefore, future studies should compare only 1 intervention strategy with 1 control group.

A potential limitation of this study was the significant amount of heterogeneity between the 11 studies. However, this limitation was addressed through subgroup analysis of intervention type, which indicated that heterogeneity was not significant within 2 of the 3 subgroups. For this reason, the interpretation of the results from the intervention subgroup analysis may be more appropriate than the pooled OR. Additionally, the 11 studies varied greatly on the percentage of people who reported IDU. Ten of the 11 studies relied on self-reported drug use and may have been influenced by bias. There was substantial variation in how and when people were randomized to the intervention and control groups. All of the studies took place in either prison or urban areas, which may affect generalizability, especially to PWID living in rural areas. Generalizability to females may also be problematic due to the majority of participants being males. Some of the studies were part of larger studies, and data for the vaccine-eligible population were not always reported. Publication bias and small-study effects may have influenced the overall findings of the study, resulting in statistically significant results. Finally, coding studies proved problematic due to the quality of reporting. Several of the studies reported conflicting information in the text, charts, and tables, making it difficult to determine the true numbers.

CONCLUSIONS

Increasing HBV vaccination is a cost-effective way of preventing both primary and secondary infections in PWID. Using accelerated vaccine schedules and financial incentives has been shown to increase compliance to the 3-dose vaccine schedule. As IDU continues, more research is needed to find strategies to improve health outcomes in this at-risk group.

Supplementary Data

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments

The authors thank Dr. George A. Kelley, Professor and Director of the Meta-Analytic Research Group at West Virginia University, for sharing his expertise in conducting the meta-analysis.

Financial support. The authors received no funding for this study.

Potential conflicts of interest. The study authors have no conflicts of interest to declare. The authors of the 11 studies included in the meta-analysis had no conflicts to declare, with the exception of 1 study that did not provide a conflict of interest statement but reported that the study was funded by GlaxoSmithKline [8]. All authors have submitted the ICJME Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Author contributions. S.T. performed the initial study search, selection of studies for inclusion in the systematic review and meta-analysis, and served as the primary coder, with R.B. as a second coder. Both S.T. and R.B. contributed to the interpretation of results, contributed to major revisions, and worked on the final manuscript.

References

1. Centers for Disease Control and Prevention. Hepatitis B. In: Hamborsky J, Kroger A, Wolfe S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Washington, DC: Public Health Foundation; 2015:149–74.
2. Harris AM, Iqbal K, Schillie S, et al. Increases in acute hepatitis B virus infections - Kentucky, Tennessee, and West Virginia, 2006–2013. MMWR Morb Mortal Wkly Rep 2016; 65:47–50.
3. Walsh N, Verster A, Rodolph M, Akl EA. WHO guidance on the prevention of viral hepatitis B and C among people who inject drugs. Int J Drug Policy 2014; 25:363–71.
4. Schillie S, Vellozi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018; 67:1–31.
5. Tran TQ, Grimes CZ, Lai D, et al. Effect of age and frequency of injections on immune response to hepatitis B vaccination in drug users. Vaccine 2012; 30:342–9.
6. Zibbell JE, Asher AK, Patel RC, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health 2016; 106:175–81.
7. Seal KH, Kral AH, Lorvick J, et al. A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend 2003; 71:127–31.
8. Christensen PB, Fisker N, Krarup HB, et al. Hepatitis B vaccination in prison with a 3-week schedule is more efficient than the standard 6-month schedule. Vaccine 2004; 22:3897–901.
9. Adi AA, Moghadami M, Zamiri N, et al. Vaccination against hepatitis B among prisoners in Iran: accelerated vs. classic vaccination. Health Policy 2011; 100:297–304.
10. Bowman S, Grau LE, Singer M, et al. Factors associated with hepatitis B vaccine series completion in a randomized trial for injection drug users reached through syringe exchange programs in three US cities. BMC Public Health 2014; 14:820. doi:10.1186/1471-2458-14-820.
11. Hwang LY, Grimes CZ, Tran TQ, et al. Accelerated hepatitis B vaccination schedule among drug users: a randomized controlled trial. J Infect Dis 2010; 202:1500–9.
12. Masson CL, Delucchi KL, McKnight C, et al. A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. Am J Public Health 2013; 103:e81–8.
13. Nyamathi AM, Sinha K, Saab S, et al. Feasibility of completing an accelerated vaccine series for homeless adults. J Viral Hepat 2009; 16:666–73.
14. Nyamathi A, Salem BE, Zhang S, et al. Nursing case management, peer coaching, and hepatitis A and B vaccine completion among homeless men recently released on parole: randomized clinical trial. Nurs Res 2015; 64:177–89.
15. Nyamathi A, Sinha K, Greengold B, et al. Predictors of HAV/HBV vaccination completion among methadone maintenance clients. Res Nurs Health 2010; 33:120–32.
16. Topp L, Day CA, Wand H, et al; Hepatitis Acceptability and Vaccine Incentives Trial (HAVIT) Study Group. A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia. Prev Med 2013; 57:297–303.
17. Weaver T, Metrebian N, Hellier J, et al. Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial. Lancet 2014; 384:153–63.
18. Julian P, Higgins P, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, England: John Wiley & Sons, Ltd; 2011.
19. A Two-Dose Hepatitis B Vaccine for Adults (Heplisav-B). JAMA 2018; 319:822–823.
20. Bridges CB, Watson TL, Nelson NP, et al. Challenges with hepatitis B vaccination of high risk adults - a pilot program. Vaccine 2019; 37:5111–20.
21. Hu Y, Grau LE, Scott G, et al. Economic evaluation of delivering hepatitis B vaccine to injection drug users. Am J Prev Med 2008; 35:25–32.
22. Heimer R, Grau LE, Singer M, et al. Hepatitis B virus prevalence and vaccination rates among hispanic injection drug users participating in a vaccination campaign. J Drug Issues 2008; 38:335–50.